Founded in 2021, A28 Therapeutics is a privately-held, clinical-stage biopharmaceutical company focused on the development of its targeted oncolytic peptide platform for the treatment of multiple cancer types.

Our lead proprietary agent, AT-101, has demonstrated the potential to deliver safe and effective cancer treatment alone and in combination with multiple classes of cancer medications including immuno-oncology medications and chemotherapy. Our lead indications are metastatic ovarian cancer with liver metastases and hepatocellular carcinoma, and we are in late-stage development in both indications. In addition, A28 is preparing to study the benefits of AT-101 in combination with immuno-oncology therapeutics in various solid tumors with liver metastases.

Our goal at A28 is to deliver innovative, game-changing cancer care to patients worldwide.

A28 Therapeutics

A28 Therapeutics' headquarters in La Jolla, CA, United States

A28 Therapeutics

Org chart

Teams

Offices

A28 Therapeutics

Org chart

Teams

Offices

Related companies